Table 2.
Proportion of patients continuing baricitinib at follow-up, for the overall cohort and patient subgroups
| Population and subgroups | 6-month follow-up |
12-month follow-up |
||
|---|---|---|---|---|
| N | n (%) | N | n (%) | |
| Overall population | 265 | 206 (77.7) | 110 | 76 (69.1) |
| Therapy subgroups | ||||
| Monotherapy | 118 | 95 (80.5) | 47 | 36 (76.6) |
| Combination therapy | 147 | 111 (75.5) | 63 | 40 (63.5) |
| Previous therapy subgroups | ||||
| bDMARD/tsDMARD naïve (prior csDMARD only) | 108 | 91 (84.3) | 49 | 36 (73.5) |
| bDMARD/tsDMARD experienced | 157 | 115 (73.3) | 61 | 40 (65.6) |
| Baricitinib dose subgroups | ||||
| 2 mg | 44 | 31 (70.5) | 19 | 10 (52.6) |
| 4 mg | 221 | 175 (79.2) | 91 | 66 (72.5) |
| Sex subgroups | ||||
| Male | 59 | 47 (79.7) | 28 | 21 (75.0) |
| Female | 206 | 159 (77.2) | 82 | 55 (67.1) |
| Age subgroups | ||||
| ≥65 years | 100 | 77 (77.0) | 46 | 29 (63.0) |
| <65 years | 165 | 129 (78.2) | 64 | 47 (73.4) |
For patients completing at least one follow-up.
bDMARD: biologic DMARD; csDMARD: conventional systemic DMARD; N: number of patients with follow-up data; tsDMARD: targeted synthetic DMARD.